LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
Toni K. Choueiri(Harvard University), Tom Powles(St Bartholomew's Hospital), Laurence Albigès(Université Paris-Saclay), M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, Marco Maruzzo(Istituto Oncologico Veneto), Alberto Suárez Zaizar, Luis Fein(Instituto de Oncología de Rosario), Fabio A. Schutz(Beneficência Portuguesa de São Paulo), Daniel Yick Chin Heng(University of Calgary), F. Wang(Exelixis (United States)), Fabio Mataveli(Exelixis (United States)), Yih‐Leong Chang(Exelixis (United States)), Maximiliano van Kooten Losio(Bristol-Myers Squibb (Switzerland)), C. Suárez Rodríguez(Vall d'Hebron Hospital Universitari), Robert J. Motzer(Memorial Sloan Kettering Cancer Center)
Cited by 20
Abstract
Related Papers
No related papers found
Powered by citation graph analysis